GlassScriptPhysician profile
Syed A Amanullah
NPI 1922435973
$4,228.44
in general payments reported to CMS, 2019-2025
25 companies · $603 in 2025
The $603 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $138 · 2021: $221 · 2022: $537 · 2023: $978 · 2024: $1,130 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,710.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $874.33 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $507.95 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $481.48 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $479.52 | 2019-2025 | Rexulti, Abilify Maintena |
| Corium, LLC | $292.68 | 2022-2025 | Azstarys |
| Abbvie INC. | $247.74 | 2021-2024 | Vraylar |
| Supernus Pharmaceuticals, INC. | $223.21 | 2023-2024 | Qelbree, Qelbree |
| Lundbeck LLC | $185.03 | 2019-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $143.06 | 2019-2024 | Jornay Pm |
| Allergan, INC. | $140.82 | 2019-2020 | |
| Axsome Therapeutics, INC. | $136.86 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.38 | 2023 | |
| Almatica Pharma LLC | $50.24 | 2024 | Loreev Xr |
| Neurocrine Biosciences, INC. | $49.94 | 2023-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $46.28 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $39.23 | 2025 | Aristada, Lybalvi |
| Shire North American Group INC | $36.57 | 2019 | |
| Idorsia Pharmaceuticals US INC | $36.30 | 2023-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $32.86 | 2025 | Jornay Pm |
| Viiv Healthcare Company | $24.75 | 2024 | Apretude |
| Lilly USA, LLC | $22.88 | 2025 | Mounjaro, Zepbound |
| Adlon Therapeutics L.P. | $17.15 | 2020 | |
| Merck Sharp & Dohme LLC | $16.33 | 2019 | |
| Pfizer INC. | $14.29 | 2023 | |
| Acadia Pharmaceuticals INC | $12.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Amanullah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.